Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugate

Antibody drug conjugates (ADCs) are no longer an unknown entity in the field of cancer therapy with the success of marketed ADCs like ADCETRIS and KADCYLA and numerous others advancing through clinical trials. The pursuit of novel cytotoxic payloads beyond the mictotubule inhibitors and DNA damaging...

Descripción completa

Detalles Bibliográficos
Autores principales: Puthenveetil, Sujiet, He, Haiyin, Loganzo, Frank, Musto, Sylvia, Teske, Jesse, Green, Michael, Tan, Xingzhi, Hosselet, Christine, Lucas, Judy, Tumey, L. Nathan, Sapra, Puja, Subramanyam, Chakrapani, O’Donnell, Christopher J., Graziani, Edmund I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448779/
https://www.ncbi.nlm.nih.gov/pubmed/28558059
http://dx.doi.org/10.1371/journal.pone.0178452

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448779/
https://www.ncbi.nlm.nih.gov/pubmed/28558059
http://dx.doi.org/10.1371/journal.pone.0178452

Ejemplares similares